iDose TR Marks the Start of a New Era in Glaucoma Care

Sticking to a daily eye drop routine can be tough. People often forget doses or have trouble using the drops correctly. That can make treatment less effective.

iDose TR removes that problem. It delivers medication continuously inside the eye, so there’s no need to remember daily drops. This steady release helps keep eye pressure stable and reduces the stress of managing a strict routine.

The implant can work for up to four years without needing to be replaced. That means fewer doctor visits and more freedom in daily life. It’s a simpler way to manage glaucoma—and a reliable option for people who want less hassle.

Many patients and caregivers wonder about the fundamental differences between iDose TR and traditional glaucoma eye drops. Traditional eye drops, while effective when used correctly, face several hurdles:

• Administration Challenges: Eye drops require precise and consistent application. Many patients find it difficult to instill drops correctly, often leading to reduced treatment effectiveness or discomfort.
• Adherence Difficulties: The need to use drops multiple times a day can be burdensome and sometimes leads to lapses in adherence. Inconsistent use can compromise fluid control within the eye.
• Variability in Drug Delivery: Eye drops provide medication in bursts rather than a controlled, continuous dosage. This can result in fluctuations in intraocular pressure throughout the day.

iDose TR addresses these challenges head on. Its continuous-release mechanism means that therapeutic levels of travoprost are maintained steadily, resulting in consistent eye pressure control. With the implant securely anchored, there’s no need to worry about missing a dose or misapplying drops. Ultimately, iDose TR simplifies treatment and helps ensure that the patient’s eye receives the consistent care it needs, all while reducing the overall treatment load.